Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tomoaki Miura is active.

Publication


Featured researches published by Tomoaki Miura.


Bioorganic & Medicinal Chemistry | 2008

Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1: Synthesis and evaluation of 12,13-carbamate and 12-arylalkylamino-13-hydroxy analogues

Tomoaki Miura; Kenichi Kurihara; Takeshi Furuuchi; Takuji Yoshida; Keiichi Ajito

Design and synthesis of 16-membered macrolides modified at the C-12 and 13 positions are described. The compounds we report here have an arylalkylamino group attached to the C-12 position of the macrolactone. Both types of derivatives, 12,13-cyclic carbamates and non-carbamate analogues, were synthesized via 12-amino-13-hydroxy intermediates derived from 12,13-epoxide that was prepared by selective epoxidation at the C-12 and C-13 positions. 4-Hydroxyl analogues were also prepared by acidic hydrolysis of a neutral sugar. These compounds were evaluated for in vitro antibacterial activity against respiratory tract pathogens. Some of these analogues exhibited an improved activity compared with the corresponding parent compound.


Bioorganic & Medicinal Chemistry | 2008

Design and synthesis of novel leucomycin analogues modified at the C-3 position. Part II: 3-O-(3-Aryl-2-propenyl)leucomycin analogues.

Takeshi Furuuchi; Tomoaki Miura; Kenichi Kurihara; Takuji Yoshida; Takashi Watanabe; Keiichi Ajito

The design and synthesis of 16-membered macrolides modified at the C-3 position are described. Starting from fully protected intermediate (5), appropriate modifications including Heck reaction were performed to furnish 3-O-(3-aryl-2-propenyl)leucomycin A(7) analogues (9a-9m). These leucomycin A(7) derivatives showed improved in vitro antibacterial activities against clinically important pathogens including erythromycin-resistant Streptococcus pneumoniae (ERSP). SAR analysis of derivatives modified at the C-3 and C-3 positions suggested that single modification at C-3 or C-3 was effective for in vitro antibacterial activity.


The Journal of Antibiotics | 2007

Novel Azalides Derived from Sixteen-Membered Macrolides

Tomoaki Miura; Satomi Natsume; Kenichi Kanemoto; Kunio Atsumi; Hideki Fushimi; Hiroaki Sasai; Takayoshi Arai; Takuji Yoshida; Keiichi Ajito

The design and synthesis of novel 15-membered 11-azalides and 16-membered 11,12-diazalide starting from 16-membered macrolides are reported. A mobile linear dialdehyde was isolated via a cyclic tetraol which was prepared by osmium oxidation of a conjugated diene. One-pot macrocyclization of this dialdehyde with an amine or a diamine afforded corresponding 15-membered azalides or 11,12-diazalide. Fundamental SAR studies of 15-membered 11-azalides disclosed their potentiality as a lead molecule for further chemical modifications. For environmental preservation, sustainable chemistry for synthesis of these azalides is also discussed.


Bioorganic & Medicinal Chemistry | 2010

Novel azalides derived from 16-membered macrolides. III. Azalides modified at the C-15 and 4″ positions: Improved antibacterial activities

Tomoaki Miura; Satomi Natsume; Kenichi Kanemoto; Eiki Shitara; Hideki Fushimi; Takuji Yoshida; Keiichi Ajito

The design and synthesis of 16-membered azalides modified at the C-15 and 4 positions are described. The compounds we report here are characterized by an arylpropenyl group attached to the C-15 position of macrolactone and a carbamoyl group at the C-4 position in a neutral sugar. Introduction of alkylcarbamoyl groups to the C-4 position was regioselectively achieved by unique and convenient methods via acyl migration. As a result of optimization at the C-3 and 15 positions, several compounds were found to have potent activity against mef- and erm-resistant bacterial strains. These results suggest that 16-membered azalides could be promising compounds as clinical candidates.


Bioorganic & Medicinal Chemistry | 2008

Novel azalides derived from 16-membered macrolides. Part II: Isolation of the linear 9-formylcarboxylic acid and its sequential macrocyclization with an amino alcohol or an azidoamine

Tomoaki Miura; Kenichi Kanemoto; Satomi Natsume; Kunio Atsumi; Hideki Fushimi; Takuji Yoshida; Keiichi Ajito

The design and synthesis of novel 14- to 16-membered 11-azalides starting from 16-membered macrolides are reported. A linear 9-formylcarboxylic acid was isolated via a mobile dialdehyde previously reported. Sequential macrocyclization of the formylcarboxylic acid with amino alcohol followed by deprotection afforded corresponding 14- to 16-membered azalides. On the other hand, reductive amination of the formylcarboxylic acid with an azidoamine followed by macrolactam formation with an amine generated from the azide gave 14- to 16-membered azalactams. Among these derivatives, 15-membered azalactams and 16-membered azalides exhibited characteristic in vitro antibacterial activities. Although optimization of 15-membered azalactams including demycarosyl analogues did not provide remarkably promising molecules, SAR studies of 16-membered azalides disclosed that substitution at the 15 position was very important for identification of a clinical candidate.


The Journal of Antibiotics | 2018

Computational study on formation of 15-membered azalactone by double reductive amination using molecular mechanics and density functional theory calculations

Hiroaki Gouda; Naofumi Nakayama; Tomoaki Miura; Kenichi Kanemoto; Keiichi Ajito

Formation of 15-membered azalactone by double reductive amination was analyzed using molecular mechanics and density functional theory calculations for simplified model compounds. As a result, the following aspects were clarified. When methylamine attacks a linear bis-aldehyde in the first step, there are possibilities that two regioisomers are formed. However, one of them exhibited remarkably stable energy level compared with the other. The stable isomer indicated a short distance between a methylamine moiety and an unreacted aldehyde. This short distance, about 2.3u2009Å, could be explained by hydrogen bonding, which implied relatively easy cyclization in the second step. Moreover, this cyclization process was supposed to be exothermic according to comparison of energy levels before and after cyclization.


Archive | 1995

Compounds with platelet aggregation inhibitor activity

Kiyoaki Katano; Shokichi Ohuchi; Tomoaki Miura; Eiki Shitara; Masaro Shimizu; Kazue Yaegashi; Naoto Ohkura; Yasuko Isomura; Hiroyuki Iida; Midori Ishikawa; Kenji Asai; Emiko Hatsushiba


Heterocycles | 2014

Sixteen-Membered Macrolides: Chemical Modifications and Future Applications

Keiichi Ajito; Tomoaki Miura; Takeshi Furuuchi; Atsushi Tamura


Archive | 1995

Novel compound having platelet aggregation inhibitor effect

Kiyoaki Katano; Shokichi Ohuchi; Tomoaki Miura; Eiki Shitara; Masaro Shimizu; Kazue Yaegashi; Naoto Ohkura; Yasuko Isomura; Hiroyuki Iida; Midori Ishikawa; Kenji Asai; Emiko Hatsushiba


Archive | 1994

Novel compound with platelet aggregation inhibitor activity

Kiyoaki Pharmaceutical Katano; Shokichi Ohuchi; Eiki Pharmaceutical Re Shitara; Masaro Shimizu; Kazue Yaegashi; Tomoaki Miura; Yasuko Isomura; Hiroyuki Iida; Midori Ishikawa; Kenji Asai; Emiko Hatsushiba; Mami Kawaguchi; Takashi Tsuruoka

Collaboration


Dive into the Tomoaki Miura's collaboration.

Top Co-Authors

Avatar

Eiki Shitara

Taisho Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Keiichi Ajito

University of California

View shared research outputs
Top Co-Authors

Avatar

Jun Kurosaka

Taisho Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Kanako Yamamoto

Taisho Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Naoki Sasamoto

Taisho Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge